Want to see CH:CMHC full AI Analyst Report?
Top Page
COSMO Pharmaceuticals N.V.
(CMHC)
Select Model
Select Model
Rating:52Neutral
Price Target:
CHF54.00
▼(-4.76% Downside)
Action:Reiterated
Date:10/25/26
The score is held back primarily by volatile profitability and a 2025 swing to negative operating and free cash flow, despite a very conservative balance sheet. Technically, the stock remains below key longer-term moving averages with a negative MACD, signaling weak trend strength. Valuation is constrained by losses (negative P/E), partially offset by a moderate dividend yield.
Positive Factors
Conservative Balance Sheet
Very low leverage and substantial equity provide financial resilience while the company manages operating volatility. This supports continued investment in gastroenterology products and technologies, preserves flexibility for partnerships or development spending, and reduces exposure to refinancing pressure.
Negative Factors
Sharp Revenue Contraction
The steep year-over-year revenue decline indicates that the latest commercial run rate is materially weaker than the prior year. If sustained, lower sales would reduce operating leverage, constrain reinvestment capacity, and make future earnings more dependent on individual products or partnership outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Very low leverage and substantial equity provide financial resilience while the company manages operating volatility. This supports continued investment in gastroenterology products and technologies, preserves flexibility for partnerships or development spending, and reduces exposure to refinancing pressure.
Read all positive factors
COSMO Pharmaceuticals N.V. (CMHC) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF897.45M
Dividend Yield3.66%
Average Volume (3M)40.44K
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue Growth-44.72%
EPS Growth-110.73%
CountryCH
Employees325
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.38
Shares Outstanding17,543,522
10 Day Avg. Volume36,874
30 Day Avg. Volume40,443
Financial Highlights & Ratios
PEG Ratio4.78
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF115.00Price Target Upside102.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.14
Revenue Forecast (FY)CHF107.24M
COSMO Pharmaceuticals N.V. Business Overview & Revenue Model
Company Description
Cosmo NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Elevie...
How the Company Makes Money
COSMO Pharmaceuticals makes money through a combination of (1) sales of its own pharmaceutical products and (2) income derived from partnering its technology and/or product rights with other pharmaceutical companies. Key revenue streams typically ...
COSMO Pharmaceuticals N.V. Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
86
Very Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 102.69M | 104.85M | 266.79M | 92.78M | 102.09M | 65.07M |
| Gross Profit | 46.74M | 48.78M | 246.92M | 53.44M | 83.33M | 49.93M |
| EBITDA | -636.78K | 2.27M | 165.71M | 18.00M | 47.49M | 18.47M |
| Net Income | -6.35M | -3.63M | 133.24M | -4.93M | 17.23M | 21.67M |
Balance Sheet | ||||||
| Total Assets | 695.64M | 612.16M | 646.77M | 553.98M | 759.59M | 805.56M |
| Cash, Cash Equivalents and Short-Term Investments | 195.28M | 122.66M | 142.96M | 50.27M | 240.95M | 222.21M |
| Total Debt | 4.33M | 4.26M | 2.20M | 1.84M | 173.60M | 169.92M |
| Total Liabilities | 121.91M | 123.36M | 141.68M | 124.94M | 295.80M | 292.88M |
| Stockholders Equity | 567.02M | 481.92M | 498.33M | 422.16M | 456.93M | 505.28M |
Cash Flow | ||||||
| Free Cash Flow | -23.82M | -15.85M | 156.76M | 18.31M | 25.92M | 4.11M |
| Operating Cash Flow | -20.08M | -11.62M | 162.41M | 22.71M | 33.23M | 12.61M |
| Investing Cash Flow | -95.36M | 49.85M | -128.88M | 42.30M | 1.69M | 24.86M |
| Financing Cash Flow | 94.90M | -24.61M | -40.22M | -211.27M | -46.13M | -27.25M |
COSMO Pharmaceuticals N.V. Technical Analysis
Neutral
56.70
Price Trends
54.52
Negative
59.76
Negative
77.14
Negative
Market Momentum
-0.73
Negative
50.55
Neutral
90.94
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:CMHC, the sentiment is Neutral. The current price of 56.7 is above the 20-day moving average (MA) of 52.35, above the 50-day MA of 54.52, and below the 200-day MA of 77.14, indicating a neutral trend. The MACD of -0.73 indicates Negative momentum. The RSI at 50.55 is Neutral, neither overbought nor oversold. The STOCH value of 90.94 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:CMHC.
COSMO Pharmaceuticals N.V. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | CHF842.87M | 16.08 | ― | 8.99% | 4.74% | -28.96% | |
66 Neutral | CHF4.39B | 27.62 | ― | 2.84% | 6.48% | -17.25% | |
62 Neutral | CHF35.49B | 65.69 | 7.04% | 0.99% | 0.81% | 165.32% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | CHF897.45M | -151.69 | -1.21% | 3.66% | -44.72% | -110.73% | |
45 Neutral | CHF1.13B | -3.20 | ― | 86.75% | -8.06% | -87.00% |
* General Sector Average
CH:CMHC
COSMO Pharmaceuticals N.V.
53.30
-13.22
-19.87%
CH:BSLN
Basilea Pharmaceutica
68.50
21.65
46.21%
CH:IDIA
Idorsia Ltd
4.19
0.76
22.10%
CH:SDZ
Sandoz Group Ltd
80.66
31.10
62.76%
CH:GALE
Galenica AG
88.10
0.02
0.02%
CH:BIOV
BioVersys AG
24.70
0.70
2.92%
COSMO Pharmaceuticals N.V. Corporate Events
Cosmo’s Rifamycin Gel Hits Key Phase 2 Mark in Distal Ulcerative Colitis
Oct 19, 2026
Cosmo Pharmaceuticals N.V., a specialty drugmaker in gastrointestinal diseases, is advancing novel locally acting therapies using proprietary liquid‑to‑gel delivery systems designed for targeted treatment of the distal colon and rectum...
Cosmo’s GI Genius AI System Boosts Adenoma Detection in Major VA Study
Sep 21, 2026
Cosmo has reported landmark real-world results for its GI Genius intelligent endoscopy platform from the CADeNCE study in U.S. Veterans Health Administration facilities. In more than 334,000 routine colonoscopies, centers using GI Genius recorded ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.